Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR

• Published in: Proceedings of the National Academy of Sciences - PNAS 2018-12, Vol.115 (51), p.12911-12919
• Main Authors: Sevilla, J. P., Bloom, David E., Cadarette, Daniel, Jit, Mark, Lipsitch, Marc
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - economics; Anti-Bacterial Agents - therapeutic use; Antibiotics; Antiinfectives and antibacterials; Antimicrobial resistance; Bacterial Vaccines - economics; Bacterial Vaccines - therapeutic use; Complementarity; Cost-Benefit Analysis; Decision Support Techniques; Drug resistance; Drug Resistance, Microbial; Economics; Gonorrhea; Gonorrhea - drug therapy; Gonorrhea - prevention & control; Health; Health Care Costs; Humans; Immunization; Immunization Programs; Medical technology; Morbidity; Neisseria gonorrhoeae - drug effects; Neisseria gonorrhoeae - immunology; Pneumococcal Infections - prevention & control; Pneumococcal Vaccines - therapeutic use; R&D; Research & development; Research - economics; Sexually transmitted diseases; Social Sciences; Socioeconomic Factors; Socioeconomics; SPECIAL FEATURE: PERSPECTIVE; STD; Vaccination - economics; Vaccines
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.1717161115

We discuss the need to make economic evaluations of vaccines antimicrobial resistance (AMR)-sensitive and ways to do so. Such AMR-sensitive evaluations can play a role in value-for-money comparisons of different vaccines within a national immunization program, or in comparisons of vaccine-centric and nonvaccine-centric technologies within an anti-AMR program. In general terms, incremental cost-effectiveness ratios and rates of return and their associated decision rules are unaltered by consideration of AMR-related value. The decision metrics need to have their various health, cost, and socioeconomic terms disaggregated into resistance-related subcategories, which in turn have to be measured carefully before they are reaggregated. The fundamental scientific challenges lie primarily in quantifying the causal impact of health technologies on resistance-related health outcomes, and secondarily in ascertaining the economic value of those outcomes. We emphasize the importance of evaluating vaccines in the context of other potentially complementary and substitutable nonvaccine technologies. Complementarity implies that optimal spending on each set of interventions is positive, and substitutability implies that the ratio of spending will depend on relative value for money. We exemplify this general point through a qualitative discussion of the complementarities and (especially the) substitutability between pneumococcal conjugate vaccines and antimicrobial stewardship and between research and development (R&D) of a gonorrhea vaccine versus R&D of a gonorrhea antibiotic. We propose a roadmap for future work, which includes quantifying the causal effects of vaccination and other health technologies on short-term and long-term resistance-related outcomes, measuring the health-sector costs and broader socioeconomic consequences of resistance-related mortality and morbidity, and evaluating vaccines in the context of nonvaccine complements and substitutes.